Literature DB >> 32385052

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.

Francesca Romana Spinelli1, Fabrizio Conti1, Massimo Gadina2.   

Abstract

JAK kinase inhibitors are being investigated as a way of managing cytokine storm in severe COVID-19 patients.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Worksce.

Entities:  

Year:  2020        PMID： 32385052     DOI： 10.1126/sciimmunol.abc5367

Source DB:  PubMed          Journal:  Sci Immunol        ISSN： 2470-9468


  49 in total

Review 1.  Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.

Authors:  Yinan Xiao; Hanyue Xu; Wen Guo; Yunuo Zhao; Yuling Luo; Ming Wang; Zhiyao He; Zhenyu Ding; Jiyan Liu; Lei Deng; Fushen Sha; Xuelei Ma
Journal:  Mol Biomed       Date:  2020-12-03

Review 2.  Recent advances in small-molecular therapeutics for COVID-19.

Authors:  Lei Zhong; Zhipeng Zhao; Xuerun Peng; Jun Zou; Shengyong Yang
Journal:  Precis Clin Med       Date:  2022-09-24

Review 3.  Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.

Authors:  Partha Palit; Aparna Mukhopadhyay; Debprasad Chattopadhyay
Journal:  Phytother Res       Date:  2021-04-04       Impact factor: 6.388

4.  An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts.

Authors:  Liuliu Yang; Yuling Han; Fabrice Jaffré; Benjamin E Nilsson-Payant; Yaron Bram; Pengfei Wang; Jiajun Zhu; Tuo Zhang; David Redmond; Sean Houghton; Skyler Uhl; Alain Borczuk; Yaoxing Huang; Chanel Richardson; Vasuretha Chandar; Joshua A Acklin; Jean K Lim; Zhengming Chen; Jenny Xiang; David D Ho; Benjamin R tenOever; Robert E Schwartz; Todd Evans; Shuibing Chen
Journal:  Circ Res       Date:  2021-04-15       Impact factor: 23.213

5.  Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.

Authors:  Eduardo Huarte; Roddy S O'Connor; Michael T Peel; Selene Nunez-Cruz; John Leferovich; Ashish Juvekar; Yan-Ou Yang; Lisa Truong; Taisheng Huang; Ahmad Naim; Michael C Milone; Paul A Smith
Journal:  Clin Cancer Res       Date:  2020-09-30       Impact factor: 12.531

6.  JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells.

Authors:  Hye Kyung Lee; Olive Jung; Lothar Hennighausen
Journal:  Commun Biol       Date:  2021-06-02

Review 7.  Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.

Authors:  Serena Colafrancesco; Rossana Scrivo; Cristiana Barbati; Fabrizio Conti; Roberta Priori
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

Review 8.  Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.

Authors:  Marisa Market; Leonard Angka; Andre B Martel; Donald Bastin; Oladunni Olanubi; Gayashan Tennakoon; Dominique M Boucher; Juliana Ng; Michele Ardolino; Rebecca C Auer
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

9.  "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.

Authors:  Shiv D Kale; Brittney N Mehrkens; Molly M Stegman; Bridget Kastelberg; Henry Carnes; Rachel J McNeill; Amy Rizzo; Saikumar V Karyala; Sheryl Coutermarsh-Ott; Jackie A Fretz; Ying Sun; Jonathan L Koff; Govindarajan Rajagopalan
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

10.  Circulating levels of IL-2, IL-4, TNF-α, IFN-γ, and C-reactive protein are not associated with severity of COVID-19 symptoms.

Authors:  Wen Luo; Jia-Wen Zhang; Wei Zhang; Yuan-Long Lin; Qi Wang
Journal:  J Med Virol       Date:  2020-06-19       Impact factor: 20.693
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.